Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Re-purposing cancer therapeutics for breast cancer immunotherapy.

Emens LA.

Cancer Immunol Immunother. 2012 Aug;61(8):1299-305. doi: 10.1007/s00262-012-1247-z. Epub 2012 Mar 28. Review.

2.

Towards a therapeutic breast cancer vaccine: the next steps.

Emens LA.

Expert Rev Vaccines. 2005 Dec;4(6):831-41. Review.

PMID:
16372879
3.

Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.

Curigliano G, Criscitiello C, Esposito A, Fumagalli L, Gelao L, Locatelli M, Minchella I, Goldhirsch A.

Breast. 2013 Aug;22 Suppl 2:S96-9. doi: 10.1016/j.breast.2013.07.018. Review.

PMID:
24074802
4.

Immunotherapy for the treatment of breast cancer.

Ernst B, Anderson KS.

Curr Oncol Rep. 2015 Feb;17(2):5. doi: 10.1007/s11912-014-0426-9. Review.

PMID:
25677118
5.

Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity.

Emens LA, Reilly RT, Jaffee EM.

Endocr Relat Cancer. 2005 Mar;12(1):1-17. Review.

6.

Augmenting the potency of breast cancer vaccines: combined modality immunotherapy.

Emens LA, Reilly RT, Jaffee EM.

Breast Dis. 2004;20:13-24. Review.

PMID:
15687703
7.

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.

Baxevanis CN, Perez SA, Papamichail M.

Cancer Immunol Immunother. 2009 Mar;58(3):317-24. doi: 10.1007/s00262-008-0576-4. Epub 2008 Aug 15. Review.

PMID:
18704409
8.

Immunotherapy strategies in the treatment of breast cancer.

Soliman H.

Cancer Control. 2013 Jan;20(1):17-21. Review.

PMID:
23302903
9.

The immune system and response to HER2-targeted treatment in breast cancer.

Bianchini G, Gianni L.

Lancet Oncol. 2014 Feb;15(2):e58-68. doi: 10.1016/S1470-2045(13)70477-7. Review.

PMID:
24480556
10.

Current and future roles of targeted therapy and immunotherapy in advanced melanoma.

Olszanski AJ.

J Manag Care Spec Pharm. 2014 Apr;20(4):346-56. Review.

11.

[New antibodies in cancer treatment].

Pestalozzi BC, Knuth A.

Praxis (Bern 1994). 2004 Sep 22;93(39):1589-92. Review. German.

PMID:
15500243
12.

Immunotherapy in Breast Cancer- Paving New Roads?

Truica CI, Cleary AS.

Curr Mol Pharmacol. 2016;9(3):208-216. Review.

PMID:
26177646
13.

Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.

Spigel DR, Socinski MA.

J Thorac Oncol. 2013 May;8(5):587-98. doi: 10.1097/JTO.0b013e318286cf88. Review.

14.

Toward a breast cancer vaccine: work in progress.

Emens LA, Jaffee EM.

Oncology (Williston Park). 2003 Sep;17(9):1200-11; discussion 1214, 1217-8. Review.

15.

[Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].

Wagner U, Köhler S, Prietl G, Giffels P, Schmidt-Nicolai S, Schlebusch H, Grünn U, Bender H, Biersack HJ, De Potter C, Krebs D, Wallwiener D.

Zentralbl Gynakol. 1999;121(4):190-5. Review. German.

PMID:
10355096
16.

Breast cancer immunotherapy.

Zhou J, Zhong Y.

Cell Mol Immunol. 2004 Aug;1(4):247-55. Review.

17.

Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.

Mohit E, Hashemi A, Allahyari M.

Expert Rev Clin Immunol. 2014 Jul;10(7):927-61. doi: 10.1586/1744666X.2014.916211. Epub 2014 May 28. Review.

PMID:
24867051
18.

Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.

Bedard PL, de Azambuja E, Cardoso F.

Curr Cancer Drug Targets. 2009 Mar;9(2):148-62. Review.

PMID:
19275756
19.

Prognostic and predictive immune gene signatures in breast cancer.

Bedognetti D, Hendrickx W, Marincola FM, Miller LD.

Curr Opin Oncol. 2015 Nov;27(6):433-44. doi: 10.1097/CCO.0000000000000234. Review.

PMID:
26418235
20.

Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.

Khawli LA, Hu P, Epstein AL.

Handb Exp Pharmacol. 2008;(181):291-328. Review.

PMID:
18071951

Supplemental Content

Support Center